
Avantor Inc. (AVTR) Stock Forecast & Price Target
Avantor Inc. (AVTR) Analyst Ratings
Bulls say
Avantor Inc. operates in a lucrative market within the healthcare sector, providing a solid avenue for expansion in margins that could align more closely with its peers, which is anticipated to result in multiple expansion over the coming years. The company has recently secured over $100 million in market share gains through contract extensions with major pharmaceutical clients, indicating strong demand for its core mAb platform and contributing to expectations of increased volume and profitability. Additionally, ongoing multi-year cost reduction initiatives are projected to exceed $250 million by the end of 2025, further enhancing the company's financial outlook and operational efficiency.
Bears say
Avantor Inc. has revised its outlook for FY25, projecting organic revenue growth to be between -2% to 0%, reflecting specific customer challenges within the bioprocessing sector and a decline in revenue during the second quarter. Additionally, the company anticipates a further decrease in organic growth for the third quarter, estimating a range of -4% to -2%, with both segments likely to contribute to this downturn. Significant headwinds from key bioprocess customers, coupled with a dip in adjusted EBITDA margins and ongoing EPS guidance reductions, suggest sustained pressure on Avantor's financial performance, which may hinder any potential recovery through 2026.
This aggregate rating is based on analysts' research of Avantor Inc. and is not a guaranteed prediction by Public.com or investment advice.
Avantor Inc. (AVTR) Analyst Forecast & Price Prediction
Start investing in Avantor Inc. (AVTR)
Order type
Buy in
Order amount
Est. shares
0 shares